Lisinopril alters contribution of nitric oxide and K(Ca) channels to vasodilatation in small mesenteric arteries of spontaneously hypertensive rats

Physiol Res. 2015;64(1):39-49. doi: 10.33549/physiolres.932780. Epub 2014 Sep 5.

Abstract

To investigate lisinopril effect on the contribution of nitric oxide (NO) and K(Ca) channels to acetylcholine (ACh)-induced relaxation in isolated mesenteric arteries of spontaneously hypertensive rats (SHRs). Third branch mesenteric arteries isolated from lisinopril treated SHR rats (20 mg/kg/day for ten weeks, SHR-T) or untreated (SHR-UT) or normotensive WKY rats were mounted on tension myograph and ACh concentration-response curves were obtained. Westernblotting of eNOS and K(Ca) channels was performed. ACh-induced relaxations were similar in all groups while L-NMMA and indomethacin caused significant rightward shift only in SHR-T group. Apamin and TRAM-34 (SK(Ca) and IK(Ca) channels blockers, respectively) significantly attenuated ACh-induced maximal relaxation by similar magnitude in vessels from all three groups. In the presence of L-NMMA, indomethacin, apamin and TRAM-34 further attenuated ACh-induced relaxation only in SHR-T. Furthermore, lisinopril treatment increased expression of eNOS, SK(Ca) and BK(Ca) proteins. Lisinopril treatment increased expression of eNOS, SK(Ca), BK(Ca) channel proteins and increased the contribution of NO to ACh-mediated relaxation. This increased role of NO was apparent only when EDHF component was blocked by inhibiting SK(Ca) and IK(Ca) channels. Such may suggest that in mesenteric arteries, non-EDHF component functions act as a reserve system to provide compensatory vasodilatation if (and when) hyperpolarization that is mediated by SK(Ca) and IK(Ca) channels is reduced.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin-Converting Enzyme Inhibitors / pharmacology*
  • Animals
  • Antihypertensive Agents / pharmacology*
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Hypertension / drug therapy*
  • Hypertension / metabolism
  • Hypertension / physiopathology
  • Intermediate-Conductance Calcium-Activated Potassium Channels / drug effects
  • Intermediate-Conductance Calcium-Activated Potassium Channels / metabolism
  • Large-Conductance Calcium-Activated Potassium Channel alpha Subunits / drug effects
  • Large-Conductance Calcium-Activated Potassium Channel alpha Subunits / metabolism
  • Lisinopril / pharmacology*
  • Male
  • Mesenteric Arteries / drug effects*
  • Mesenteric Arteries / metabolism
  • Mesenteric Arteries / physiopathology
  • Nitric Oxide / metabolism*
  • Nitric Oxide Synthase Type III / antagonists & inhibitors
  • Nitric Oxide Synthase Type III / metabolism
  • Potassium Channel Blockers / pharmacology
  • Potassium Channels, Calcium-Activated / drug effects*
  • Potassium Channels, Calcium-Activated / metabolism
  • Rats, Inbred SHR
  • Rats, Inbred WKY
  • Signal Transduction / drug effects
  • Small-Conductance Calcium-Activated Potassium Channels / drug effects
  • Small-Conductance Calcium-Activated Potassium Channels / metabolism
  • Vasodilation / drug effects*
  • Vasodilator Agents / pharmacology*

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Antihypertensive Agents
  • Intermediate-Conductance Calcium-Activated Potassium Channels
  • Kcnma1 protein, rat
  • Large-Conductance Calcium-Activated Potassium Channel alpha Subunits
  • Potassium Channel Blockers
  • Potassium Channels, Calcium-Activated
  • Small-Conductance Calcium-Activated Potassium Channels
  • Vasodilator Agents
  • Nitric Oxide
  • Lisinopril
  • Nitric Oxide Synthase Type III
  • Nos3 protein, rat